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ABSTRACT 22 
Better understanding alveolarization mechanisms could help improve prevention and treatment of 
diseases characterized by reduced alveolar number. Although signaling through fibroblast growth 
factor (FGF) receptors is essential for alveolarization, involved ligands are unidentified. FGF18, the 
expression of which peaks coincidentally with alveolar septation, is likely to be involved. Herein, a 
mouse model with inducible, lung-targeted FGF18-transgene was used to advance the onset of FGF18 
expression peak, and genome-wide expression changes were determined by comparison with 
littermate controls. Quantitative RT-PCR was used to confirm expression changes of selected up and 
down regulated genes, and to determine their expression profiles in the course of lung postnatal 
development. This allowed identifying so far unknown target genes of the factor, among which a 
number are known to be involved in alveolarization. The major target was adrenomedullin, a promoter 
of lung angiogenesis and alveolar development, whose transcript was increased 6.9-fold. Other genes 
involved in angiogenesis presented marked expression increases, including Wnt2 and cullin2. 
Although it appeared to favor cell migration notably through enhanced expression of Snai1/2, FGF18 
also induced various changes consistent with prevention of epithelial-mesenchymal transition. 
Together with anti-fibrotic effects driven by induction of E prostanoid receptor 2 and repression of 
numerous myofibroblast markers, this could prevent alveolar septation-driving mechanisms from 
becoming excessive and deleterious. Last, FGF18 up or down regulated genes of ECM components 
and epithelial-cell markers previously shown to be up or down regulated during alveolarization. These 
findings therefore argue for an involvement of FGF18 in the control of various developmental events 
during the alveolar stage. 
 23 
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27 
INTRODUCTION 28 
Lung alveolarization, the formation process of definitive alveoli, is a complex developmental event 29 
that extends from the last gestational weeks to the 2 first postnatal years. In rats and mice that are 30 
classical model animals for studying its underlying mechanisms, it is entirely postnatal; subdivision of 31 
alveolar sacs by secondary septation takes place between days 4 and 14 (although recent investigations 32 
have indicated that new alveoli can be generated later from mature septa), and septal maturation with 33 
fusion of double capillary layer into a single layer is terminated on day 20. Alveolarization involves a 34 
variety of regulatory factors, but its control is only partially understood (5) . Deciphering these 35 
mechanisms is of particular importance because they are profoundly disturbed in chronic lung disease 36 
of the premature neonate also known as “new” bronchopulmonary dysplasia (BPD) (19) or in lung 37 
hypoplasia consecutive to congenital diaphragmatic hernia (CDH) (3) . Furthermore, maintenance of 38 
alveolar structure necessitates the persistence of at least some of these control pathways in the adult 39 
lung, which appears to be disordered in emphysema (6). 40 
 Alveolarization is abolished in mice simultaneously devoid of fibroblast growth factor (FGF) 41 
receptors (FGFR) 3 and 4 (49). Despite normal elastic fiber gene expression in isolated lung interstitial 42 
cells, excessive elastin deposition occurs in this model with loss of typical spatial restriction, and 43 
epithelial cells contribute to the observed abnormalities (42). Thus far however, the identity of 44 
involved FGF(s) has remained elusive. The assumption that FGF18 is involved is based on the facts 45 
that (i) this mediator, similar to the most homologous other FGF-family members FGF8 and FGF17, 46 
binds FGFR4 and the IIIc-form of FGFR3 with high affinity (12, 39), and (ii) a strong rise of FGF18 47 
expression occurs when secondary septation starts in 3 species, namely the rat (7), the mouse (8, 30) 48 
and man (3). Most strikingly, secondary septation coincides precisely with the peak of  lung FGF18 49 
expression that falls abruptly after its ending in the rat and the mouse (7, 8, 30). Indeed, FGF18 level 50 
could not be studied until completion of alveolar development in man because this occurs during the 51 
second postnatal year.  52 
Although it is expressed at a lower rate earlier, there are evidences for FGF18 involvement in 53 
previous lung developmental stages already. Conditional expression of FGF18 in the lung of 54 
transgenic mouse fetuses from embryonic day 6 to term thus caused distal airways to adopt structural 55 
features of proximal airways with abnormal cartilage deposition, suggesting a role in the control of 56 
proximal differentiation program during pseudoglandular/canalicular stages (51). FGF18 was 57 
accordingly reported to control chondrogenesis in upper airways (11). These findings, however, do not 58 
enlighten the functional significance of the marked postnatal peak of FGF18 expression, when the 59 
tract of cartilage-containing conducting airways is complete. Another investigation evidenced reduced 60 
air space, thicker interstitial mesenchymal compartments, and presence of embedded capillaries in the 61 
prenatal lung consequently to Fgf18 gene targeting in mice, which indicates involvement at saccular 62 
stage also (45). Consistently, FGF18 expression was found to be enhanced in the stimulation of fetal 63 
rat lung growth induced by tracheal ligation (34). Unfortunately, FGF18 gene targeting cannot be used 64 
to investigate FGF18 role during alveolar stage because Fgf18-/- pups do not survive beyond birth.  65 
Although FGF18 implication in alveolarization has therefore not yet received demonstration, it is 66 
nevertheless further supported indirectly by several observations. Thus, FGF18 stimulated ex vivo 67 
proliferation of perinatal rat lung fibroblasts and enhanced their expression of elastic fiber components 68 
(7), two events that occur during alveolar septation. Last, although FGF18 is unexplored in BPD, 69 
decreased FGF18 expression was found to be associated with impaired alveolarization in 2 instances, 70 
(i) a rat model of BPD (28) and (ii) human lung hypoplasia consecutive to CDH (3).   71 
To document the molecular effects of FGF18 and try to explore the physiological significance of its 72 
sharp postnatal expression peak, the Tet-On system-based mouse model of conditional FGF18 73 
expression in the lung designed by Whitsett et al. (51) was used here to provoke a rise of FGF18 in the 74 
perinatal period, hence inducing precociously an increase of expression similar to the one occurring 75 
after birth during secondary alveolar septation. Pups were collected before the onset of septation, i.e. 76 
before the rise of endogenous FGF18. This timing was chosen because we assumed that inducing the 77 
expression of the transgene later, during the stage of secondary septation, might have added little to 78 
the effects of endogenous FGF18-gene expression. In view of the considerable rise of the latter during 79 
this stage, responses are likely to be high, and even possibly maximal. Gene profiling study was then 80 
performed on genome-wide expression microarrays to identify genes up or down regulated by induced 81 
FGF18 expression. Double transgenic mouse pups bearing both the inducible FGF18 transgene and 82 
the inducer construct were compared to controls bearing only the silent FGF18 transgene. Some of the 83 
affected genes were selected on the basis of both their known functions and the extent of FGF18 84 
effects to confirm changes by quantitative RT-PCR and to determine their expression profile during 85 
postnatal development. We thus identified as FGF18 targets a variety of genes the involvement of 86 
which in alveolarization is either demonstrated or likely, which argues for specific FGF18 functions in 87 
postnatal lung development. 88 
 89 
MATERIAL AND METHODS 90 
Wild type mice, transgenic mice and treatments 91 
Wild type FVB/N mice were purchased from Charles River Laboratories (Saint Germain sur 92 
l'Arbresle, France). The transgenic mouse model has been described in detail previously (45). In brief, 93 
mice bearing the inducible construct (teto)7-CMV-FGF18 transgene were bred to SP-C-rtTA mice in 94 
which the expression of the rtTA activator construct is targeted on alveolar epithelial type II cells by 95 
the promoter of surfactant protein C. Mice bearing the transgenic constructs were bred in an FVB/N 96 
background from two male founders obtained from the Cincinnati Children’s Research Foundation. 97 
Animal experiments were performed under license from the Animal Health and Protection Service of 98 
the French Ministry of Agriculture. Because FGF18 expression in mouse lung increases postnatally to 99 
peak on days 7 to 10 (8, 30), the inducer doxycycline was given from prenatal day 2 (E18) to postnatal 100 
day 2 (P2) in order to induce earlier an expression peak similar to the one occurring during alveolar 101 
septation. Pup lungs were collected aseptically on P3 under pentobarbital anesthesia and kept frozen at 102 
-80°C until use or fixed at constant pressure for histological analysis. Experimental protocol is 103 
summarized in Fig.1. 104 
 105 
Lung morphology and morphometry 106 
Methods used in this study have been described in detail previously (28). Briefly, lung fixation was 107 
performed by tracheal infusion of neutral buffered paraformaldehyde at constant 20cm H2O pressure, 108 
and fixed lung volume was measured by fluid displacement. After routine processing and paraffin 109 
embedding, 4-µm-thick mediofrontal sections through both lungs were stained with picro-indigo- 110 
carmine for morphological pictures or with hematoxylin-phloxine-saffron for morphometry. Alveolar 111 
airspace, airways, blood vessels larger than 20 µm in diameter, interstitial tissue volume densities and 112 
the alveolar surface density were determined using the point counting and mean linear intercept 113 
methods (48). Light microscope fields were quantified at an overall magnification of x440 on 20 fields 114 
per animal (10 per lung) with a systematic sampling method from a random starting point. All 115 
morphometric analyses were performed by a single observer (BCH) who was unaware of group 116 
assignment.  117 
 118 
Genotyping and assessment of FGF18-transgene expression 119 
Genotyping was performed on DNA extracted from mouse-tails by use of the ChargesSwitch® gDNA 120 
kit Mini Tissue kit from Invitrogen (Cergy-Pontoise, France) using the following primers for PCR in a 121 
Hybaid thermocycler: for SP-C-rtTA, 5’-GACACATATAAGACCTGGTC-3’ (forward) and (5’-122 
AAAATCTTGCCAGRCTTCCCC-3’ (reverse); for (teto)7-FGF18, 5’-GCCATCCACGCTCTTTG-3’ 123 
(forward primer located in the CMV minimal promoter) and 5’-124 
CAGGACTTGAATGTGCTTCCCACTG-3’ (reverse primer located in the FGF18 cDNA). The two 125 
last primers were also used in doxycycline-treated pups to assess specifically the FGF18-transgene 126 
expression response by semi-quantitative RT-PCR on total RNAs extracted from lung tissue. 127 
Quantitative RT-PCR for total FGF18 transcript was performed as described below (primers in table 128 
1). 129 
 130 
Generation of cRNA “target” and chip hybridization  131 
Total RNA was extracted from lung tissue using the guanidinium isothiocynate method (TRIzol 132 
reagent, Invitrogen, Cergy-Pontoise, France), followed by purification using Rneasy columns (Qiagen, 133 
Courtaboeuf, France). Four pairs of control ((teto)7-CMV-FGF18) and double-transgenic (SP-C-rtTA , 134 
(teto)7-CMV-FGF18) pups, each pair being issued from a different litter (i.e. 4 different litters and 4 135 
biological replicates for each condition) were selected on the basis of FGF18 transgene induction. 136 
Integrity and purity of RNA were checked by spectrophotometry and capillary electrophoresis, using 137 
the Bioanalyser 2100 and RNA 6000 LabChip kit from Agilent Technologies (Palo Alto, CA). cDNAs 138 
and biotin-labeled-cRNAs were successively synthesized using Superscript Choice system 139 
(Invitrogen) and Affymetrix IVT labeling kit (Affymetrix, Santa Clara, CA, USA), respectively. After 140 
purification, 10 µg of fragmented cRNA were hybridized to the Affymetrix GeneChip® Mouse 141 
Genome 430 2.0 Array (>39,000 transcripts). Each of the 4 control samples and of the 4 double-142 
transgenic samples was hybridized individually on one chip (no technical replicates). Chips were 143 
automatically washed and stained with streptavidine-phycoerythrin. Arrays were scanned at 570 nm 144 
with a resolution of 1.56 µm/pixel using Affymetrix Gene Chip Scanner 3000. Expression values were 145 
generated using Microarray Suite v5.0 (MAS5, Affymetrix). Each sample and hybridization 146 
experiment underwent a quality control evaluation (table 2).   147 
  148 
Microarray data analysis  149 
Gene expression values were extracted from cell-probe values using the affy package (16) of the R 150 
software (15). Rma2 implementation of Robust Multiarray Averaging (17), qspline (55), pmonly and 151 
liwong (25) were used as methods of background correction, normalization, pm-correction and 152 
summarization, respectively. In order to assess replicability, the pair-wise correlations were computed 153 
between the 8 arrays. The lowest value (0.976266) indicated excellent overall replicability. 154 
Concerning intra-condition replicability, lowest values were 0.9921674 for controls and 0.979491 for 155 
double-transgenic pups. For gene selection, a one-tailed t-test for paired values was computed for both 156 
over and under-expressions. Paired t-test was used because each of the 4 double-transgenic pups was 157 
compared to its corresponding littermate control that had experienced same environment during the 158 
experiment. Because directional changes were searched for, i.e. gene expressions presenting univocal 159 
increases or decreases in all the 4 double-transgenic samples, a one–tailed t-test was used. Features 160 
were then ranked with respect to their P-value, and the list of features in the best 1% was determined. 161 
We computed the mean of the logratios, ranked the features and selected the top 0.5 for each direction 162 
of differential expression. The intersection of those 2 lists was selected for further analysis.  163 
 164 
Reverse transcription (RT) and real-time quantitative polymerase chain reaction (qPCR)  165 
RNAs extracted as described above were reverse-transcribed into cDNAs using 2 µg of total RNA, 166 
Superscript II reverse transcriptase, and random hexamer primers (Invitrogen) according to the 167 
supplier’s protocol. Real-time PCR was performed on ABI Prism 7000 device (Applied Biosystems, 168 
Courtaboeuf, France) using initial denaturation (10 min at 95°C), then two-step amplification program 169 
(15 s at 95°C followed by 1 min at 60°C) repeated 40 times. Melt curve analysis was used to check 170 
that a single specific amplified product was generated. Reaction mixtures consisted of 25 ng cDNA, 171 
SYBR Green 2X PCR Master Mix (Applied Biosystems), and forward and reverse primers for the 172 
various examined transcripts (displayed in table 1) in a reaction volume of 25 µl. Primers were 173 
designed using Primer Express software (Applied Biosystems). Real-time quantification was 174 
monitored by measuring the increase in fluorescence caused by the binding of SYBR Green dye to 175 
double-stranded DNA at the end of each amplification cycle. Relative expression was determined by 176 
using the ∆∆Ct (threshold cycle) method of normalized samples (∆Ct) in relation to the expression of 177 
a calibrator sample used to normalize data from one plate to another, according to the manufacturer’s 178 
protocol. Each PCR run included a no-template control and a sample without reverse transcriptase. All 179 
measurements were performed in triplicates. Both 18S rRNA and the housekeeping gene Hprt1 180 
mRNA were used as references and provided similar values (see below, Results section). For in vivo 181 
effects of FGF18-transgene induction, individual data were expressed as a percentage of the mean 182 
control value (single-transgenic pups) in each litter. For developmental expression profiles (lungs of 183 
wild type mice), data were expressed as percentage of P0 (neonates) level. Control and double-184 
transgenic comparisons of gene-expression directional changes were made by one-tailed t test. For 185 
developmental expression profiles, considering the small sample size (4 individuals from 2 different 186 
litters per stage), non-parametric tests were used: multiple stage comparisons were made by Kruskal-187 




FGF18-transgene expression and lung morphology/morphometry in doxycycline-treated mouse 192 
pups 193 
As evaluated on P3, induction of FGF18 transgene in the lung was observed in all litters, although its 194 
rate varied widely among individuals and litters. In the 4 double-transgenic individuals selected for 195 
chip hybridization, FGF18 transgene amplification was manifest as estimated by semi-quantitative 196 
RT-PCR run with specific primers (Fig. 2). In those samples, quantification of total FGF18 expression 197 
by microarray analysis indicated 11.7-fold average increase (range: 1.5- to 20-fold), and that by RT-198 
qPCR 6.35-fold average increase (range: 1.8- to 22-fold). In the 11 double-transgenic pups from 5 199 
different litters used to confirm by RT-qPCR the changes evidenced by microarray data, it was 200 
similarly increased over 6-fold as compared to 10 single-transgenic littermates (2ΔΔct: 13.37 ± 2.96 vs 201 
2.14 ± 0.16, respectively, and 641.9 ± 143.1% of controls vs 100.0 ± 6.3%, P<0.001). Although the 202 
level might have varied along treatment, this is indicative of the extent of transgene induction. 203 
Morphology of lung parenchyma appeared unaffected in double transgenic pups as compared to either 204 
wild-type or single-transgenic pups (Fig. 3). Morphometric analysis performed on pups that had 205 
undergone the same doxycycline-treatment protocol as those used for gene-expression analysis 206 
indicated no significant change in double-transgenic pups for lung volume, mean linear intercept, or 207 
alveolar surface area, either on P4 when secondary septation starts, or on P8 or P16 when it is more 208 
advanced and terminated, respectively (table 3). 209 
 210 
Array data analysis 211 
Primary microarray data are available at the Gene Expression Omnibus Database 212 
(www.ncbi.nih.gov/geo/ GEO accession number: GSE22283). Statistical analysis retrieved 487 genes 213 
and EST significantly up-regulated, and 1235 genes and EST significantly down-regulated by FGF18 214 
induction. Only characterized genes with defined function(s) were considered further. Fold-change of 215 
the 77 up-regulated genes ranged from 1.12-fold to 4-fold their respective basal expression levels in 216 
single-transgenic controls. Maximum expression decrease of down regulated genes was about 70%. In 217 
order to avoid exceedingly large tables and discussion about limited expression changes only genes 218 
with expression increased or decreased at least 25% are displayed in tables 4 and 5, respectively (i.e. 219 
32 up-regulated genes including five genes of particular interest increased 22.4 to 24.2%, and 104 220 
down-regulated genes). 221 
Data from RT-qPCR determinations used to confirm expression changes of selected genes and to 222 
determine their developmental expression profiles were referred to both 18S rRNA and Hprt1 mRNA.  223 
Although absolute values provided by both references were slightly different, they indicated the same 224 
proportional changes (Table 6). The use of either reference therefore did not affect conclusions. 225 
Because 18S rRNA level displayed constant proportionality with the amount of extracted RNAs and 226 
more stable 2-ΔΔct (i.e. more constant level) than Hprt1 mRNA across the developmental period under 227 
study, data presented below are those using 18S rRNA as reference.    228 
 229 
Genes up regulated by FGF18 induction 230 
To facilitate comparisons, the developmental profile of endogenous FGF18 is presented along with 231 
those of genes up regulated by FGF18-transgene induction (Fig. 4, bottom). FGF18 transcript was 232 
enhanced on P4 and further on P7 as compared with P0 level, then dropped on P14 and further on P28, 233 
and reached very low level in adult lung. Following transgene induction, the gene with most strongly 234 
increased expression (4-fold) was that of the vasoactive peptide adrenomedullin (Adm). RT-qPCR 235 
analysis on a larger number of pups indicated even stronger stimulation (almost 6.9-fold, table 7). 236 
Adm was followed by CD36 antigen (also known as fatty acid translocase), and hydroxysteroid 11β 237 
dehydrogenase 1 (Hsd11b1), which was confirmed by RT-qPCR although changes were found to be 238 
slightly (CD36) or largely (Hsd11b1) higher than those detected by microarrays (table 7). The 239 
postnatal expression profiles of these 3 genes in normal lung shared a 2.5- to 5-fold decrease between 240 
days P0 and P4 (Fig. 4), an event that appeared to have been prevented by FGF18 induction in 241 
transgenic pups. This was followed by re-increase from P4 but with different patterns. Adm transcript 242 
rose sharply from P4, peaked from P7 to P14, then fell to retrieve low level on P20 onwards (Fig. 4), 243 
displaying therefore a profile resembling that of endogenous FGF18 expression, except for the P4 244 
decrease. CD36 expression also re-increased rapidly from P4 whereas that of Hsd11b1 re-increased 245 
more gradually, but contrary to Adm, both maintained high level until day 28 and returned to low level 246 
in adult lung only (Fig. 4). CD36 expression level varied widely among individuals. 247 
In addition to fibulin 1 expression already known to be enhanced by FGF18 (7), the expression of 248 
various extracellular matrix (ECM) components was increased. These include bone sialoprotein (or 249 
integrin binding sialoprotein, Ibsp), chondroitin sulfate proteoglycan 2 (table 4), and chondromodulin-250 
1b (not included in table 4). RT-qPCR confirmed bone sialoprotein and fibulin 1 changes, the steady-251 
state level of their transcripts being increased 2.8 times and 1.69 times, respectively (table 6). Their 252 
developmental profiles presented high level during the period of secondary septation and a drop on 253 
day 14 (Fig. 4), consistent with control by endogenous FGF18. 254 
FGF18 induction up-regulated the expression of a variety of genes involved in antioxidant 255 
metabolism, including glutathione-S-transferase mu5 (Gstm5), ceruloplasmin, leucine-rich α2-256 
glycoprotein-1 (Lrg1) cytochrome P450 (Cyp) 2e1, cysteine dioxygenase 1, adrenodoxin (table 4), 257 
serine hydroxymethyl transferase, carbonyl reductase 1, and SH3-binding domain glutamic acid-rich 258 
protein like (Sh3bgrl) (not included in table 4). Again, expression changes determined by RT-qPCR 259 
for the mostly affected genes Gstm5 and ceruloplasmin were larger than those from microarrays, 260 
reaching 3.2-fold and 2.6-fold, respectively (table 7). Gstm5 developmental expression profile 261 
displayed increase from P4 to P7, fall on day 14, and further decrease to very low level in adulthood, 262 
consistent with control by endogenous FGF18 (Fig. 4). By contrast, that of ceruloplasmin displayed 263 
postnatal decrease, no significant change from P4 to P10, moderate decrease on P14, increase on P28, 264 
and maintenance of sizeable level in adult lung, which argues for multifactorial control involving 265 
factors other than FGF18. 266 
FGF18 induction also more or less enhanced (+50% to +16%) the expression of genes the protein 267 
products of which are known to stimulate or are likely to be involved in cell migration, including 268 
wingless-related MMTV integration site 2 (Wnt2), snail homologs 1 and 2 (Snai1, Snai2), sushi-repeat 269 
protein, mixed-lineage kinase-like mitogen-activated triple kinase alpha (MLTKα), and neural 270 
precursor cell-expressed developmentally down-regulated gene 9 (Nedd9). Importantly, it 271 
simultaneously stimulated (+100% to +16.5%) the expression of genes the products of which have 272 
opposite and antifibrotic effects, including (in addition to CD36 antigen already mentioned) Th2-273 
specific cytokine FISP/IL24, Borg4/binder of Rho GTPase 4, prostanoid E receptor EP2 subtype 274 
(Ptger2) (table 4), and the tumor suppressor Lim domains-containing protein 1 (Limd1, not included in 275 
table 4). RT-qPCR analysis run for Wnt2, Snai1, Snai2, and Ptger2 confirmed enhancement with 276 
larger changes than those detected by microarray analysis (table 7), particularly marked for Wnt2 and 277 
Snai2 (2.4-fold each). Developmental expression profiles of these 4 genes were very similar, with high 278 
level during alveolar septation, maximum on P7-10, abrupt drop on P14, and low level during 279 
alveolar-wall maturation and in adult lung (Fig. 4), consistent with regulation by FGF18.  280 
Last, in keeping with its effects on lung-fibroblast proliferation (7), FGF18 enhanced the 281 
expression of a variety of genes involved in cell growth and ribosome synthesis, including G0G1 282 
switch gene 2, brix domain containing 1 (Bxdc1), NIMA-related expressed kinase 8 (Nek8) (table 4), 283 
and more slightly (not included in table 4), mitogen activated protein kinase kinase 1 (Map2k1), 284 
mitogen activated protein kinase kinase kinase 8 (Map3k8), cyclin D2, ribosomal proteins S2 and S13, 285 
mitochondrial-ribosomal protein S18B, and WD repeat domain 12 (Wdr12). 286 
 287 
Genes down regulated by FGF18 induction 288 
Six genes presenting over 50% decreased expression (table 5) included the adipocyte markers (also 289 
expressed in alveolar type II cells) C1q and tumor necrosis factor related protein 3 (C1qtnf3 or 290 
CTRP3, also known as cartducin, cartonectin, or collagenous repeat-containing sequence of 26kdA 291 
protein [CORS 26]), stearoyl-Coenzyme A desaturase 1 (Scd1), and Ca(2+)-sensitive chloride channel 292 
2, the alveolar type II cell marker ATP-binding cassette transporter 3 (ABCA3), the ECM component 293 
osteoglycin (Ogn), and the ECM-degrading enzyme, fibroblast activation protein (Fap) also designated 294 
Seprase. Other ECM and connective tissue components, including proteoglycan 4, chondrolectin, 295 
asporin, matrilins 1 and 2, thrombospondin 4 and chondroadherin, and another ECM-degrading 296 
enzyme, Adamts 5, had notably reduced expression (-47% to -30%, table 5). The transcript of the 297 
transcription factor high mobility group box protein / SRY-box containing gene (Sox2), another gene 298 
with epithelium-restricted expression, was reduced by 40%. RT-qPCR analysis confirmed the decrease 299 
for C1qtnf3, Scd1, ABCA3 (-49%, -69%, -48%, respectively), but not for Sox 2, Ogn and Fap (table 300 
8). As regards Sox 2, Ogn and Fap, although RT-qPCR confirmed lower levels in those samples used 301 
for microarray hybridization, the variability between and inside litters was so wide for single- as well 302 
as for double-transgenic pups that no significant change was observed on the average in the 11 double-303 
transgenic pups compared to their 10 control littermates. Moreover, there was no correlation between 304 
individual values and the extent of FGF18 changes in double-transgenic pups, suggesting the 305 
fortuitous character of variations. Developmental expression profiles were established for C1qtnf3, 306 
Scd1 and ABCA3 (Fig. 5). C1qtnf3 transcript rose from P0 to P4, which was unlikely to be related to 307 
endogenous FGF18, decreased then gradually until P14, which could relate to FGF18 peak, and 308 
decreased further until adulthood. Scd1 transcript increased modestly from P4 to P14, then strongly 309 
until P28 to decline in adult lung. ABCA3 transcript declined half on P4, rose about twice on days 7-310 
10, which could indeed not be due to endogenous FGF18, then decreased about twice on P14 and 311 
remained stable thereafter. 312 
Two genes whose protein products are related to retinoic acid (RA) metabolism, cellular RA 313 
binding protein 1 (Crabp1), aldehyde dehydrogenase family 1, subfamily A1 (Aldh1a1) displayed 314 
reduced expression in microarray findings (-45% and -40%, respectively). This was confirmed by RT-315 
qPCR for Crabp1 (-59%) but not for Aldh1a1 for the same reasons as above (table 8). However, 316 
Crabp1 developmental profile presented huge increase from P4 to P14 and decreased then 317 
progressively to extremely low level in adult lung (Fig. 5). This profile is not consistent with a 318 
negative control by endogenous FGF18 since both transcripts evolve in parallel during development.  319 
FGF18 induction reduced to variable extent the expression of various genes related with cell 320 
migration and invasion, including doublecortin (Dcx, -48%), plasminogen activator inhibitor type II 321 
(PAI2/Serpinb2, -39%), cytoplasmic polyadenylation element binding protein (Cpeb, -30%), and 322 
semaphorin 5A (-29%) (table 5), and more modestly PAI1/Serpine 1 (-23%, not included in table5). 323 
RT-qPCR analysis of Dcx confirmed decrease (table 7). As for Crabp1, Dcx developmental expression 324 
profile looked similar to that of FGF18 with peak from P7 to P10 and fall on P14 (Fig. 5), which 325 
indicates that endogenous FGF18 does not exert negative control. 326 
In addition to ABCA3, FGF18 induction reduced the expression of a variety of alveolar and/or 327 
bronchiolar (Clara) epithelial cell markers, including cytochrome oxidases Cyp1b1 (confirmed by RT-328 
qPCR, table 7), Cyp2f2 and Cyp2b10, aquaporins 3 and 4, uteroglobin-related protein 329 
1A/secretoglobin (Scgb3a2), aldehyde oxydase 3, and claudin 8. Expressions of other genes related 330 
with oxidant/detoxification/xenobiotic metabolism, namely Cyp2b20, Cyp4b20, Cyp2f2, cytochrome 331 
oxydase subunits VIIa and VIIIb, vanin1 (table 5), and Cyp2b20 (-21%, not included in table 5), were 332 
also diminished. The developmental expression profile of Cyp1b1 was consistent with down 333 
regulation by endogenous FGF18: initially elevated at birth, it decreased abruptly to minimum level 334 
maintained from d7 to d20, re-increased slightly on d28, and decreased again in adult lung (Fig. 5). 335 
Last, FGF18 induction decreased the expression of a variety of contractile cell markers, including 336 
troponins C, I and T3, myomesin 1, chondrolectin, actinin alpha 2, mouse alpha cardiac myosin heavy 337 
chain, calponin 1, myomesin 2, actins gamma 2 and alpha 1, dystrophin, caveolin 3, and calsequestrin 338 
2 (-45% to -25%, table 5). Interestingly, expression of the specific myofibroblast markers calponin 1 339 




Using a mouse transgenic model, we found that advancing the peak of pulmonary FGF18 expression 344 
affected the expression level of numerous genes in a variety of pathways. Despite apparent 345 
complexity, most of these effects can be filed into 3 main groups that deal with (i) angiogenesis, (ii) 346 
cell migration, and (iii) expression of ECM components. Although alveolarization was not advanced 347 
by FGF18 induction, these effects are suggestive of FGF18 involvement in alveolarization 348 
mechanisms.  349 
 350 
Putative FGF18 target cells in the lung considering FGF18 receptor expression.  351 
FGF18 binds with high affinity the IIIc splice variant of FGFR3 and the unique form of FGFR4, and 352 
more modestly the IIIc splice variant of FGFR2, but presents no affinity for IIIb isoforms (12, 39). 353 
Considering FGFR expression pattern, all cell types of lung parenchyma are potential targets of 354 
FGF18 through one or two receptors. Thus, if FGFR2 IIIc variants are expressed exclusively in 355 
mesenchyme-derived tissues, both lung mesenchymal and alveolar epithelial cells express FGFR3 and 356 
FGFR4 (41), although it is unknown whether they express differentially FGFR3IIIb and IIIc. 357 
Pulmonary endothelial cells and vascular smooth muscle cells are likely to express FGFR2IIIc and 358 
FGFR3IIIc, since these have been characterized in human umbilical vascular endothelial cells 359 
(HUVEC) and aortic smooth muscle cells (2). Indeed, direct although different biological effects of 360 
FGF18 have been demonstrated on cultured cells of the different types. Specifically, FGF18 enhanced 361 
lung fibroblast proliferation and let unchanged epithelial-cell proliferation (7), whereas it induced 362 
BMP4 expression in tracheal epithelial cells (14). HUVEC displayed chemotaxis toward FGF18, but 363 
failed to proliferate in response to the factor (1). Studying changes in gene expression level in whole 364 
lung therefore allows one to detect changes occurring in any of potential target cells. However, this 365 
prevents from identifying any compartmentalization influence, except for genes known to present 366 
expression restricted to one cell type. The present study should therefore be completed by future 367 
investigations aiming at spatial determination of FGF18 effects.   368 
 369 
Limitations of the study.  370 
One could raise an objection that lack of morphological changes after precocious induction of FGF18 371 
expression argues against the involvement of the factor in alveolarization mechanisms. However, 372 
considering the complexity of alveolarization and the multiplicity of involved control factors (5) it is 373 
not surprising that the induction of a single factor, even if actually involved, was insufficient alone to 374 
induce precociously the whole process. More questionable are apparently paradoxical effects of 375 
transgenic FGF18 such as markedly increased CD36 and Hsd11b1 expressions. Although endogenous 376 
FGF18 might contribute to their expression re-increase from P4, their profiles, contrary for instance to 377 
that of Adm, do not coincide with that of FGF18. Hsd11b1 expression remains at low relative level 378 
during septation when FGF18 peaks. CD36 expression remains elevated and that of Hsd11b1continues 379 
increasing when FGF18 expression falls to maintain maximal level until P28, i.e. 14 days after FGF18 380 
fall down. This appears inconsistent with control by FGF18 only, and presumably results from 381 
complex changes in the balance of various antagonistic control mechanisms.  382 
Nonetheless, the herein described maintenance of Hsd11b1 expression at levels much lower than P0 383 
level during septation period is novel and developmentally highly significant. Although in cell-free 384 
system, this interconverting enzyme of cortisone and cortisol behaves mainly as a dehydrogenase 385 
(inactivation), in vivo it is considered to perform 11β-reduction (activation) (10). Because 386 
corticosteroids have been reported to inhibit septation and to terminate alveolarization through fusion 387 
of the double capillary layer and thinning of septa (32, 43), low pulmonary corticosteroid activation 388 
subsequent to low Hsd11b1 expression level therefore appears as requisite for septation. Pursued 389 
elevation of Hsd11b1 expression between days 14 and 28 appears conversely to relate to 390 
corticosteroid-driven septation arrest and maturation of septa. 391 
Several issues could account for difficulty in interpreting FGF18-induced effects. In the lung, FGF18 392 
is released by interstitial cells (3, 7, 51), and possibly endothelial cells (2). The use of SP-C regulatory 393 
sequence to target FGF18 transgene expression on alveolar epithelial type II cells therefore leads to 394 
ectopic expression. This might have changed local availability of the factor, and it cannot be ruled out 395 
that this might have affected the responsiveness of its target cells, which could have been somehow 396 
different from that to FGF18 expressed from endogenous gene. Also likely to be involved in possible 397 
differences appear changes in cellular microenvironment, i.e. interaction of FGF18 with signal 398 
molecules either different or present in different relative proportions in the pre- and postnatal lung. 399 
Hence, paradoxical changes observed in double-transgenic pups might have been permitted by 400 
conditions prevailing around birth that were different from those during alveolarization. In addition, 401 
difficulties could be inherent to the model itself because of possible toxicity of the SP-C-rtTA 402 
transgene and because doxycycline is a pan-MMP (matrix metalloproteinase) inhibitor while MMPs 403 
play a functional role in alveolarization (discussed in 52). The absence of lung morphological changes 404 
in developing (this study) or adult (51) mice of this strain however argues against this assumption. 405 
Last, RT-qPCR post-hoc analysis gave more consistent results for up-regulated than for down-406 
regulated genes. This appeared to be due to wide random expression variations of genes that presented 407 
by chance lower expression in those 4 double-transgenic lung samples used for microarray analysis. 408 
Because it was indeed not possible to perform individual RT-qPCR control for all gene expressions 409 
found to be diminished in microarray data, decreases were considered to be effective when there was 410 
consistency for several genes among a group (e.g. cell-type markers or genes encoding products with 411 
similar functions or involved in a same pathway). These considerations point the interest of examining 412 
the developmental expression profile of putative target genes to interpret results from transcriptome 413 
analysis.  414 
 415 
Adrenomedullin and genes involved in angiogenesis.  416 
The primary target of FGF18 was Adm gene, the expression of which was increased about 7-fold by 417 
transgene induction. Adm developmental expression profile, which, similar to that of FGF18  418 
displayed peak coincidental with secondary septation, was consistent with control by endogenous 419 
FGF18. Adrenomedullin is hypoxia-inducible peptide with vasodilator, antioxidative and angiogenic 420 
properties, highly expressed in the developing lung. Not only has Adm been reported to regulate cell 421 
growth and survival, to induce proliferation and migration of endothelial progenitor cells, to enhance 422 
the regenerating potential of the latter for pulmonary endothelium (36), and to regenerate alveoli and 423 
vasculature in elastase-induced pulmonary emphysema (35), but its role in alveolar development was 424 
recently evidenced (46). Lung expression of its transcript increases during alveolar development in rat 425 
lung also, and Adm requirement for alveolar septation and angiogenesis was demonstrated in this 426 
species (46). Whereas intranasal administration of an adrenomedullin-antagonist decreased lung 427 
VEGF expression and capillary density, and impaired alveolar development, giving exogenous 428 
adrenomedullin in a hyperoxic model of BPD reciprocally attenuated arrested lung angiogenesis and 429 
alveolar development (46).  430 
FGF18-transgene induction also enhanced expression of other genes likely to be involved in 431 
angiogenesis, including Wnt2, a growth and differentiation factor for endothelial cells (22). This is 432 
consistent with decreased Wnt2 expression reported in compound FGFR3/4 mutant mice (42). 433 
Although more modestly, FGF18 also enhanced the expression of cullin 2 (not shown in table 4), 434 
which is required for vascular development through regulation of VEGF transcription mediated by 435 
hypoxia-inducible factor α (29).  436 
The importance of FGF18 for angiogenesis had been evidenced previously in other organs by its 437 
chemotactic effect for endothelial cells (1) and by delayed skeletal vascularization in FGF18-/- mice 438 
(27). Consistently, vessel size and PECAM labeling were increased in the lung of SP-C-rtTA/(teto)7-439 
FGF18 mouse fetuses treated with doxycycline during whole gestation (51). Our findings now identify 440 
FGF18 as a likely important player in the control of alveolar angiogenesis, an event that is absolute 441 
requirement for alveolarization and is compromised in BPD. 442 
 443 
FGF18 effects related with cell migration. 444 
FGF18 is known to drive cell migration, especially for endothelial cells (1, 27), which is in keeping 445 
with effects of FGF18 transgene on a panel of genes involved in this process. In addition to Adm, 446 
these include the zinc-finger transcription factor-encoding genes Snai1 (Snail) and Snai2 (Slug), sushi 447 
repeat protein, Lrps 1 and 2, and Nedd 9. However, in addition to promotion of cell movement during 448 
organogenesis, SNAI proteins are also well known to be involved in epithelial-mesenchymal transition 449 
(EMT) and metastatic invasion (37). In the lung, their overexpression was sufficient to induce EMT in 450 
alveolar epithelial cells whereas SNAI depletion conversely attenuated TGFβ1-induced cell migration 451 
and EMT (18). Up regulation of Wnt2 and down regulation of Sfrp1, both induced by FGF18, are also 452 
involved in EMT (20). Although these FGF18 effects could therefore appear as favoring EMT, there is 453 
no EMT during normal alveolar development. EMT is by contrast encountered in pathological 454 
condition, namely lung fibrosis, via activation of endogenous latent TGFβ1 (21). Among other 455 
possible mechanisms, prevention of EMT during alveolarization could be due to the simultaneous 456 
induction of counteracting mechanisms by FGF18, including (i) down-regulation of genes encoding 457 
factors involved in cell invasion and metastasis such as doublecortin (13), PAI1 and PAI2 (33), and 458 
semaphorin 5A (40), and (ii) up-regulation of genes that inhibit spreading of mesenchyme-derived 459 
cells including fibulin-1 (53) and FISP/IL24 (9).  460 
Also consistent appears the FGF18-induced reduced expression of numerous muscle-cell markers, 461 
which are expressed in the lung by smooth muscle cells and myofibroblasts. FGF18 thus reduced 462 
notably the expression of genes that are known to be down-regulated at initiation of mouse lung 463 
alveolarization (54), but were conversely up-regulated in TGFβ1-induced fibroblast-to-myofibroblast 464 
transdifferentiation (44) or in experimental hyperoxia-induced BPD (47). Prostaglandin E2 has been 465 
repeatedly reported to modulate lung inflammation and to prevent the fibroblast-to-myofibroblast 466 
transition through E prostanoid receptor 2 (Ptger2) signal (23, 50). Taken together, the increased 467 
number of pulmonary myofibroblasts in compound FGFR3/4 mutant mice (42) and the increased 468 
expression of Ptger2 consecutive to FGF18 induction evidenced herein strongly argue for a 469 
physiological role of FGF18 in prevention of fibrosis. Although myofibroblast differentiation and 470 
migration are necessary to alveolarization (26), FGF18 might prevent these from becoming excessive 471 
and falling over into EMT and fibrosis. 472 
 473 
474 
Effects on ECM components.  475 
FGF18 strongly enhanced the expression of the ECM components bone sialoprotein, chondroitin 476 
sulfate proteoglycans, and fibulin 1. Fibulin 1 is clearly indispensable to normal alveolar development 477 
(24). The role of bone sialoprotein in alveolarization is unknown, but its expression peak coincidental 478 
with secondary septation and its angiogenic properties (38) argue for involvement. As regards 479 
chondroitin sulfate proteoglycans, they are known to be present in alveolar basement membrane. 480 
FGF18 conversely decreased the expression of a variety of other ECM components. Previous 481 
investigations (4, 31, 54) have evidenced clusters of ECM-component genes up regulated either early 482 
during the phase of secondary septation or later during maturation of septa. FGF18 appears as an 483 
inducer of genes belonging to the former group. Interestingly, the expression of the ECM-related 484 
genes asporin and microfibrillar protein 5 that was increased in FGFR3/4-null mice (42) was 485 
conversely decreased by FGF18 induction, suggesting that FGF18 decreases expression of the late-486 
group genes. 487 
 488 
Other effects.  489 
FGF18 enhanced the expression of a variety of cytochrome oxidases and of genes involved in 490 
antioxidant mechanisms. The postnatal developmental expression profiles of glutathione-S-transferase 491 
and ceruloplasmin, with high postnatal level and fall on day 14, were consistent with control by 492 
FGF18. This is interesting in a therapeutic perspective, because preterm infants have immature 493 
antioxidant defense mechanisms and increased susceptibility to oxidative stress, which in turn is 494 
precipitating factor of BPD. Conversely, FGF18 down regulated a number of P450 cytochrome 495 
oxidases and other genes involved in xenobiotic metabolism. Numerous cytochrome oxidases with 496 
FGF18-decreased expression, including Cyp2b10, Cyp2b20, Cyp2f2 and Cyp4b1 were recently found 497 
to be down regulated in the alveolarizing postnatal lung (54). It was suggested that these changes 498 
could be related to expansion of epithelial precursor cell pool through balance between proliferation 499 
and differentiation of epithelial cells (54). Consistent with this assumption is the FGF18-diminished 500 
expression of a number of genes expressed selectively in lung epithelial cell subsets, including Ca(2+)-501 
sensitive chloride channel 2, Abca3, Cyp1b1, Cyp2f2, stearoyl coenzyme A dehydrogenase (Scd1), 502 
aquaporins 3 and 4, uteroglobin-related protein 1a, and aldehyde oxidase 3. However, targeting the 503 
expression of FGF18 transgene on type II cells by the use of SP-C promoter might have enhanced 504 
these effects.  505 
Lastly, it is worth pointing that, although not consistent with a negative control by endogenous 506 
FGF18, the developmental expression profile of Crabp1 remarkably presents a peak coincidental with 507 
alveolar septation. Taking into account the central role of RA released by lipofibroblasts in 508 
alveolarization (5), this appears to correspond to maximal capacity of lung cells to link and retain RA. 509 
 510 
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 675 
Figure legends 676 
Fig. 1. Experimental protocol for doxycycline treatment and lung sample collection. In order to induce 677 
precocious expression of FGF18, advanced as compared with endogenous peak, transgenic SP-C-678 
rtTA- and (teto)7-FGF18-mice were bred, and their progeny (gathering both single and double 679 
transgenic individuals, and rarely wild type individuals) was treated by the inducer doxycycline. 680 
Pregnant mice received first doxycycline in drinking water (0.5mg/ml) for the 2 last prenatal days. 681 
Doxycycline was removed from drinking water on the day of birth (designated postnatal day 0 or P0), 682 
and pups received then one daily subcutaneous injection of doxycycline aqueous solution 3 mg/ml (20 683 
mg/kg bw) on P0, P1 and P2. Their lungs were collected on P3 and kept at -80°C until RNA extraction 684 
for gene-expression analyses, or on P4, P8 or P16 for lung fixation and morphological/morphometric 685 
analyses. Post-hoc genotyping of the pups was performed on DNA extracted from tail fragment. 686 
 687 
Fig. 2. Semi-quantitative RT-PCR analysis of (teto)7-FGF18 transgene expression in the 8 mouse pup 688 
lung samples used for microarray hybridization. Transgene-specific primers were used as stated in 689 
M&M, 25 amplification cycles were run. Lane 1, molecular-size ladder; lane 2, sample D4, SP-C-690 
rtTA/(teto)7-FGF18 (double transgenic), litter 1; lane 3, sample D2, (teto)7-FGF18 (single-transgenic 691 
control), litter 1; lane 4, sample D34, SP-C-rtTA/(teto)7-FGF18, litter 2; lane 5, sample D40, (teto)7-692 
FGF18, litter 2; lane 6, sample D48, SP-C-rtTA/(teto)7-FGF18, litter 3; lane 7, sample D50, (teto)7-693 
FGF18, litter 3; lane 8, sample D52, SP-C-rtTA/(teto)7-FGF18, litter 4; lane 9, sample D58, (teto)7-694 
FGF18, litter 4. FGF18-transgene expression was manifest in double-transgenic pups bearing both the 695 
inducible FGF18 transgene and the activator construct whereas it was not or barely detectable in their 696 
littermates bearing only the FGF18 transgene. 697 
 698 
Fig. 3. Morphological aspects of mouse lungs on postnatal day 4. Pups were issued from a same litter 699 
and were treated by doxycycline as stated in M&M and Fig. 1. Lungs were collected on P4 that 700 
revealed as the earliest stage for adequate pressure fixation in this species. Lungs were fixed with 701 
paraformaldehyde at constant pressure, embedded in paraffin, cut at 4µm and stained by picro-indigo- 702 
carmine. A. Wild-type mouse pup. B double-transgenic pup (SP-C-rtTA/(teto)7-FGF18). C. Single-703 
transgenic pup ((teto)7-FGF18). Morphology was similar in the 3 instances.  704 
 705 
Fig. 4. Developmental expression profile from birth to adulthood in wild-type mouse lung of 11 genes 706 
with expression found to be increased by FGF18-transgene induction in microarray analysis. 707 
Quantitative RT-qPCR was used to determine expression levels. Endogenous-FGF18 expression 708 
profile is also displayed for facilitating comparisons. Mean ± se on 4 individual lung samples from 2 709 
different litters per stage (absence of error bar means that it was too small to be represented at this 710 
scale). Multiple stage comparison was made by Kruskal-Wallis analysis, followed by two-stage 711 
comparisons by Mann and Whitney U test. To avoid overloading of the graphs, significant differences 712 
are not represented, but significant changes are detailed in text. Gene symbols: Adm, adrenomedullin; 713 
Hsd11b1, hydroxysteroid 11β dehydrogenase 1; Gstm5, glutathione-S transferase, mu5; Wnt2, 714 
wingless-related MMTV integation site 2, Snai, snail homolog, Ptger2, prostaglandin R receptor EP2 715 
subtype. 716 
 717 
Fig. 5. Developmental expression profile from birth to adulthood in wild-type mouse lung of 6 genes 718 
with expression found to be decreased by FGF18-transgene induction in microarray analysis. 719 
Quantitative RT-qPCR was used to determine expression levels. Mean ± se on 4 individual lung 720 
samples from 2 different litters per stage (absence of error bar means that it was too small to be 721 
represented at this scale). Multiple stage comparison was made by Kruskal-Wallis analysis, followed 722 
by two-stage comparisons by Mann and Whitney U test. To avoid overloading of the graphs, 723 
significant differences are not represented, but significant changes are detailed in text. Gene symbols: 724 
C1qtnf3, C1q and tumor necrosis factor related protein 3; Scd1, stearoyl-coenzyme A desaturase 1; 725 
Abca3, ATP-binding cassette transporter ABCA3; Dcx, doublecortin, Crabp1, cellular retinoic acid 726 
binding protein 1; Cyp1b1, cytochrome P450, 1b1. 727 
 728 
Table 1. Sequence of primers used for RT-qPCR determinations  729 
 730 
Gene name (official symbol; accession number) Forward primer (5’-3’) Reverse primer (5’-3’) 
Fibroblast growth factor 18 (FGF18; NM_008005) TGAACACGCACTCCTTGCTAGT GAATTCTACCTGTGTATGAACCGAAA 
Adrenomedullin (Adm; NM_009627) GAAGGACTTCTTTCTGCTTCAAGTG GCGAGTGAACCCAATAACATCA 
CD36 antigen (cd36; NM_007643) GCAAAGTTGCCATAATTGAGTCCTA CTGCGTCTGTGCCATTAATCA 
Hydroxysteroid 11-beta dehydrogenase 1 (Hsd11b1; NM_007643) TCTCTGTGTCCTTGGCCTCATA CACTCCTCCTTGGGAGAAGCT 
Bone sialoprotein (Ibsp1; NM_008318) CATGCCTACTTTTATCCTCCTCTGA AACTATCGCCGTCTCCATTTTC 
Glutathione S transferase mu5 (Gstm5; NM_010360) GGACGTGAAATTCAAGCTAGATCTG CTTGTTCTTCCCGTCCATGAG 
Ceruloplasmine (Cp; NM_007752) TGCTGGGATGGCAACTACCT CGTTTTCCACTTATCGCCAATT 
Wingless-related MMTV integration site 2 (Wnt2; NM_023653) CTGGACAGAGATCACAGCCTCTT GCGTAAACAAAGGCCGATTC 
Snail homolog 2 (Snai2; NM_011415) AAGCCCAACTACAGCGAACTG CGAGGTGAGGATCTCTGGTTTT 
Fibulin 1 (Fbln1; NM_010180 ) ACCAAGAAGACCCGTACCTGAA GTCACGGCACTGCTGCTTAC 
Prostaglandin E receptor EP2 subtype (Ptger2; NM_008964) GCCTTTCACAATCTTTGCCTACAT GACCGGTGGCCTAAGTATGG 
Snail homolog 1 (Snai1; NM_011427) GGGCGCTCTGAAGATGCA GTTGGAGCGGTCAGCAAAAG 
C1q and tumor necrosis factor related protein 3 (C1qtnf3; 
NM_030888) 
GCACAACGGCAACACAGTCT TGCATGGTTGCTGGATGTATC 
StearoylCoA desaturase 1 (Scd1; NM_009127) CCATGCAGGCAGGTAGTGGTA TGCCCATGTCTCTGGTGTTTTA 
ATP-binding cassette transporter 3 (ABCA3; AY083616) AGCCAACATAGCAGCAGCC TACCGAGGAGCCACGAAAAA 
Osteoglycin (Ogn; NM_008760) CAGATGATACATTCTGCAAGGCTAA CCTCCAGGCGAATCTCTTCA 
Fibroblast activation protein (Fap; NM_007986) TGATTCTGCCTCCTCAGTTTGA CAGACTTAACACTCTGGCTGCAA 
Doublecortin (Dcx; NM_010025) AAAAACTCTACACCCTTGATGGAAA TGCATTCATTCTCATCCAAGGA 
Cellular retinoic acid binding protein 1 (Crabp1; NM_013496) GGGCTTCGAGGAGGAGACA TGTGCAGTGAATCTTGTTCTCATTC 
SRY-box containing gene (Sox2; NM_011443)  AGATGCACAACTCGGAGATCAG GCTTCTCGGTCTCGGACAAA 
Aldehyde dehydrogenase 1, subfamily A1 (Aldh1a1; NM_013467) GGCTCTTCACCTGGCATCTTT CCCATAACCAGGGACAATGTTT 
Cytochrome P450, 1b1 (Cyp1b1; NM_009994) AGGTTGAAGCCTTGCCAGAA TGCTGTGGACTGTCTGCACTAA 
 731 
732 
Table 2. Evaluation of quality filter criteria in microarrays 733 
 734 
Sample Scale factor % P Ratio 3’/5’ actin Ratio 3’/5’ GAPDH 
(validation threshold) Max/Min<3 >20 and Max-Min<15 <4 <4 
D2-C 0.504 60.4 1.25 0.77 
D4-DT 0.582 59.5 1.30 0.93 
D34-C 0.661 59.3 1.26 0.74 
D40-DT 0.643 60.7 1.25 0.87 
D48-C 0.635 60.6 1.25 0.78 
D50-DT 0.486 60.8 1.25 0.81 
D52-C 0.544 60.2 1.25 0.76 
D58-DT 0.606 60.0 1.27 0.77 
Mean ± se 0.580 ± 0.023 60.19 ± 0.20 1.26 ± 0.006 0.804 ± 0.004 
 735 
Each sample and hybridization experiment underwent a quality control evaluation, including percentage of probe sets reliably 736 
detecting between 59.3% and 60.8% Present call, and 3’-5’ ratios of actin and GAPDH genes <1.3 and <1, respectively. %P: 737 










                       P4                          P8 
 
                        P16
 controls double transgenic controls double transgenic controls double transgenic 
n 10 9 8 8 14 8 
VL (cm3) 0.135 ± 0.009 0.152 ± 0.010 0.249 ± 0.014 0.271 ± 0.017 
 
0.376 ± 0.015  
 
0.392 ± à.027  
Sva (cm2/cm3) 294 ± 12 277 ± 10 340 ± 18 293 ± 17 
 
361 ± 12 
 
358 ± 17 
Vvp (%) 0.964 ± 0.007 0.986 ± 0.019 0.989 ± 0.002 0.992 ± 0.002 
 
0.995 ± 0.001 
 
0.992 ± 0.002 
MLI (µm) 13.8 ± 0.5 14.6 ± 0.5 12.0 ± 0.7 14.0 ± 0.8 
 
11.3 ± 0.4 
 
11.3 ± 0.5 
Sa (cm2) 38 ± 3 41 ± 2 83 ± 6 79 ± 7
 
135 ± 7 
 
139 ± 10 
 747 
 748 
Treatment with doxycycline was the same as that for animals used for microarray analysis. Pups were collected from 3 or 4 749 
litters per stage at postnatal days 4, 8 or 16. Data are mean ± SE. Abbreviations: n, number of individuals per group; VL, lung 750 
volume; Sva, alveolar surface density; Vvp, volumetric density of lung alveolar parenchyma; MLI, mean linear intercept; Sa, 751 
absolute surface area of airspaces. No significant difference was observed between the 2 groups for any parameter either at 752 
P4, P8 or P16 (two-tailed t-test). 753 
754 
Table 4. Results of array analysis: genes up regulated at least 25%* by FGF18 induction in the 4 755 
double-transgenic mouse pups as compared to their respective littermate single-transgenic controls 756 
(one-tailed paired t test). 757 
 758 
Accession # Name Funct. Cat. 
log2-fold 
change fold change P value  
NM_009627  adrenomedullin (Adm) Signal, Angio 2.02628 x 4.074 0.0494
NM_007643  CD36 antigen Lmetab+Antifib 1.06464 x 2.092 0.0463 
NM_008288  hydroxysteroid 11-beta dehydrogenase 1 (Hsd11b1) Enz, Ster metab 1.00447 x 2.0 0.0364 
NM_008318  bone sialoprotein (integrin-binding sialoprotein, IBSP) ECM+Recept 0.83998 x 1.79 0.014 
NM_010360  glutathione S-transferase, mu 5 (Gstm5) Enz, Antiox 0.75917 x 1.693 0.0379 
NM_007752  ceruloplasmin (Cp) Enz, Antiox 0.72622 x 1.654 0.0393 
NM_023653  wingless-related MMTV integration site 2 (Wnt2) Signal, Angio+Migr 0.58788 x 1.5 0.0357 
NM_029796   leucine-rich alpha-2-glycoprotein 1 (Lrg1) Antiox 0.55743 x 1.472 0.0028 
NM_021282   cytochrome P450, 2e1, ethanol inducible (Cyp2e1) Enz, Antiox 0.55580 x 1.47 0.0305 
BI964347  a disintegrin and metalloproteinase domain 12 (meltrin alpha) Enz, ECM 0.54291 x 1.457 0.0283 
NM_033037   cysteine dioxygenase 1, cytosolic (Cdo1) Enz, Antiox 0.51247 x 1.426 0.037 
AF333251  Th2-specific cytokine FISP/IL24 Signal, Antifib 0.48965 x 1.4 0.0417 
NM_010023  dodecenoyl-Coenzyme A delta isomerase (Dci) Enz, Lmetab 0.48113 x 1.4 0.0077 
C77655  CD84 antigen Immun 0.46537 x 1.381 0.0311 
NM_011415  snail homolog 2 (Drosophila) (Snai2) Signal, Migr+EMT 0.45841 x 1.374 0.0412 
NM_010180   fibulin 1 (Fbln1) ECM+Antifib 0.45225 x 1.368 0.0354 
BB131147   Borg4-pending /binder of Rho GTPase 4 Recept, Antifib 0.44920 x 1.365 0.0261 
BQ176864  protein phosphatase 1, regulatory (inhibitor) subunit 3C (Ppp1r3c) Enz, Glyc metab  0.43991 x 1.357 0.0408 
BC028307  Similar to sushi-repeat protein Migr 0.43074 x 1.348 0.0257 
NM_010717   LIM-domain containing, protein kinase (Limk1) Enz, Antifib 0.42335 x 1,341 0,006 
NM_011146   peroxisome proliferator activated receptor gamma (Pparg) Signal, Lmetab 0.41266 x 1.331 0.0425 
NM_008118  gastric intrinsic factor (Gif) Transport 0.38563 x 1.306 0.0403 
NM_008059   G0G1 switch gene 2 (G0s2) Prolif 0.37920 x 1.3 0.0334 
X14607  lipocalin 2 / Mouse SV-40 induced 24p3 mRNA Migr 0.35332 x 1.277 0.0197 
NM_011611  tumor necrosis factor receptor superfamily, member 5 (Tnfrsf5) Signal, Immun  0.33640 x 1.263 0.0425 
NM_023323  brix domain containing 1 (Bxdc1) Prolif 0.33067 x 1.258 0.0237 
BC008277  Similar to Endothelin receptor type A Recept, Angio 0.32332 x 1.251 0.0207 
NM_008964  prostaglandin E receptor EP2 subtype (Ptger2) Recept, Antifib 0.31244 x 1.242 0.0427 
NM_019389   chondroitin sulfate proteoglycan 2 (Cspg2) ECM 0.30793 x 1.238 0.0234 
NM_080849  NIMA-related expressed kinase 8 (Nek8) Enz, Prolif 0.29273 x 1.225 0.0356 
NM_007996  adrenodoxin Antiox 0.29229 x 1.225 0.0264 
NM_011427  snail homolog 1, (Drosophila) (Snai1) Signal, Migr+EMT 0.29147 x 1.224 0.0213 
 759 
*Five genes of interest increased 22.4 to 24.2% have been added to the list.      760 
Abbreviations: Funct. Cat., functional category of gene product; Angio, angiogenesis; Antifib, anti-fibrotic effects; Antiox, 761 
anti-oxidant metabolism; ECM, extracellular-matrix component or metabolism; EMT, epithelial-mesenchymal transition; 762 
Enz, enzyme or enzyme inhibitor; Glyc metab, glycogene megtabolism; Immun, immune system; Lmetab, lipid metabolism; 763 
Migr, cell migration; Prolif, cell proliferation; Recept, receptor; Signal, signaling molecule; Ster metab, steroid metabolism; 764 
Transport, transporter molecule. 765 
Genes with name and symbol in bold character had changes checked by RT-qPCR. 766 
767 
Table 5. Results of array analysis: genes down regulated at least 25% by FGF18 induction in the 4 768 
double-transgenic mouse pups as compared to their respective littermate single-transgenic controls 769 
(one-tailed paired t test). 770 
 771 
Accession # Name Funct. Cat. 
log2-fold 
change fold change P value  
NM_030888  C1q and tumor necrosis factor related protein 3 (C1qtnf3/cartonectin) Signal, Lipog -1.59897 x 0.33 0.0094 
NM_030601  Ca(2+)-sensitive chloride channel 2 (Cacc) Transport, Epm -1.39070 x 0.381 0.0039 
NM_009127  stearoyl-Coenzyme A desaturase 1 (Scd1) Enz, Lipog -1.28176 x 0.411 0.0088 
AY083616  ATP-binding cassette transporter ABCA3  Transport, Epm -1.05604 x 0.481 0.0004 
NM_008760  osteoglycin (Ogn) ECM -1.04551 x 0.484 0.0088 
NM_007986  fibroblast activation protein (Fap/seprase) Enz, ECM, Migr -1,02764 x 0.491 0.0002 
AK007703  homolog to ATP-binding cassette transporter, sub-family A, member 3  Transport, Epm -0.97681 x 0.508 0.0003 
NM_010025  doublecortin Migr -0.94387 x 0.52 0.0103 
NM_021400  proteoglycan 4 (Prg4) ECM -0,92209 x 0.528 0.0187 
NM_009181  sialyltransferase 8 (alpha-2, 8-sialytransferase) B (Siat8b) Enz, Glycoconj  -0.89706 x 0.537 0.0265 
NM_009608  actin, alpha, cardiac (Actc1) MCm -0.88653 x 0.541 0.0397 
NM_009393  troponin C, cardiac/slow skeletal (Tncc1) MCm -0.86216 x 0.55 0.0262 
NM_013496  cellular retinoic acid binding protein I (Crabp1) Retino metab -0.85952 x 0.551 0.0373 
NM_011674  UDP-glucuronosyltransferase 8 Enz, Detox -0.82905 x 0.563 0.0247 
NM_013808  cysteine-rich protein 3 (Csrp3) MCm -0.80843  x 0.571 0,0064 
NM_010867  myomesin 1 (Myom1) MCm -0.79768 x 0.575 0.0049 
AF311699  c-type lectin protein MT75 (chondrolectin) ECM -0.79070 x 0.578 0.0003 
NM_015825  SH3-binding domain glutamic acid-rich protein (Sh3bgr) MCm -0.78637 x 0.581 0.0121 
NM_033268  actinin alpha 2 (Actn2) MCm -0.77289 x 0.585 0.0405 
NM_013834   secreted frizzled-related sequence protein 1 (Sfrp1) Prolif, EMT -0.76298 x 0.589 0.0005 
NM_010858  myosin light chain, alkali, cardiac atria (Myla) MCm -0.75605 x 0.592 0.0373 
NM_018870  phosphoglycerate mutase 2 (Pgam2) Enz, Inter metab -0.74443 x 0.597 0.0268 
NM_011620  troponin T3, skeletal, fast (Tnnt3) MCm -0.73578 x 0.6 0.0170 
NM_011443  high mobility group box protein (SRY-box containing gene 2, Sox2) Trancrip, Epm -0.72852 x 0.6 0.0028 
NM_013467  aldehyde dehydrogenase family 1, subfamily A1 (Aldh1a1) Retino metab -0.71960 x 0.607 0.0216 
NM_011111  plasminogen activator inhibitor, type II (Serpinb2) Signal, Migr -0.71960 x 0.607 0.0019 
NM_016689  aquaporin-3 Transport, Epm -0.69277 x 0.619 0.0330 
NM_009944  cytochrome c oxidase subunit VIIa-H precursor (Cox7ah) Enz, Detox -0.68876 x 0.62 0.0211 
NM_011395  solute carrier family 22 (organic cation transporter), member 3 (Slc22a3) Transp -0.68500 x 0.622 0.0149 
NM_010856  Mouse alpha cardiac myosin heavy chain  (Myhca) MCm -0.67333 x 0.627 0.0422 
NM_009922  calponin 1 (Cnn1) MCm -0.66432 x 0.631 0.0093 
BB193413  aquaporin 4 (Aqp4) Transport, Epm -0.65006 x 0.637 0.0335 
AF274959  uteroglobin related protein 1A / secretoglobin (Scgb3a2) Transport, Epm -0.64771 x 0.638 0.0196 
NM_008973  pleiotrophin Sign -0.64583 x 0.639 0.0007 
AF128849  cytochrome P450 2B10 related protein (Cyp2b20) Enz, Detox -0.63401 x 0.644 0.0318 
NM_010356  glutathione S-transferase, alpha 3 (Gsta3) Enz, Detox -0.63049 x 0.646 0.0207 
NM_033597  myeloblastosis oncogene (Myb) Transcript -0.61924 x 0.65 0.0174 
NM_021396  butyrophilin-like protein (Btdc) Immun -0.61661 x 0.652 0.0013 
NM_008182  glutathione S-transferase, alpha 2 (Yc2) (Gsta2) Enz, Detox -0.61598 x 0.652 0.0069 
NM_009405  troponin I, skeletal, fast 2 (Tnni2) MCm -0.61569 x 0.653 0.0417 
NM_011704  vanin 1 (Vnn1) Detox -0.60899 x 0.656 0,0001 
NM_009676  aldehyde oxidase 1 (Aox1) Enz,  -0.60447 x 0.658 0.0047 
NM_023785  pro-platelet basic protein (Ppbp) Signal, Immun -0.59965 x 0.66 0.0094 
NM_018778  claudin 8 Epm -0.59480 x 0.662 0.0003 
NM_009994  cytochrome P450, 1b1, benz(a)anthracene inducible (Cyp1b1) Enz, Detox -0.59413 x 0.662 0.0115 
NM_008165  glutamate receptor, ionotropic, AMPA1 (alpha 1) (Gria1) Recept -0.59078 x 0.664 0.0020 
NM_008592  forkhead box C1 (Foxc1) Trancript -0.59037 x 0.664 0.0382 
NM_007710  creatine kinase, muscle (Ckmm) Enz, MCm -0.58630 x 0.666 0.0162 
NM_007617  caveolin 3 Signal, MCm -0.58227 x 0.668 0.0273 
NM_007933  enolase 3, beta muscle (Eno3) Enz, MCm -0.57902 x 0.669 0.0328 
NM_009998  cytochrome P450, 2b10, phenobarbitol inducible, type b (Cyp2b10) Enz, Detox -0.57377 x 0.672 0.0312 
NM_008469  keratin complex 1, acidic, gene 15 (Krt1-15) Epm -0.56978 x 0.674 0.0318 
NM_008419  potassium voltage-gated channel, member 5 (Kcna5) Transport -0.56587 x 0.676 0.0363 
NM_007817 cytochrome p450, 2f2 (Cyp2f2) Enz, Detox -0.56285 x 0.677 0.0185 
NM_013494  Carboxypeptidase E Enz Prot metab -0.56262 x 0.677 0.0022 
NM_013712  integrin beta 1 binding protein 2 Recept, ECM -0.56174 x 0.677 0.0013 
NM_009814  calsequestrin 2 (Casq2) MCm -0.55415 x 0.681 0.0379 
BQ174827  doublecortin and calciumcalmodulin-dependent protein kinase-like 1  Enz, Prot metab -0.55458 x 0.68 0.0137 
NM_007429  angiotensin II receptor, type 2 (Agtr2) Recept -0.55246 x 0.682 0.0302 
    NM_011098  Brx1a mRNA for homeoprotein Transcript, MCm -0.54870 x 0.684 0.0102 
AF356844  carboxypeptidase Z Enz, Prot metab -0.54419 x 0.685 0.0292 
NM_007751  cytochrome c oxidase, subunit VIIIb (Cox8b) Enz, Detox -0.53763 x 0.689 0.0133 
NM_011782  a disintegrin-like and metalloprotease 5 (aggrecanase-2) (Adamts5) Enz, ECM -0.53751 x 0.689 0.0316 
NM_023478  uroplakin 3 (Upk3) Epm -0.53425 x 0.69 0.0132 
NM_008664  myomesin 2 MCm -0.53029 x 0.692 0.0172 
NM_009610  actin, gamma 2, smooth muscle, enteric (Actg2) MCm -0.52433 x 0.695 0.0404 
NM_007868  dystrophin, muscular dystrophy (Dmd) MCm -052267 x 0.696 0.0067 
  NM_080462.  histamine N-methyltransferase (Hnmt) Enz, Immun -0.52095 x 0.697 0.0221 
NM_023617  aldehyde oxidase 3 (Aox3) Retino metab -0.51687 x 0.699 0.0094 
NM_025711  asporin (Aspn) ECM -0.51470 x 0.7 0.0146 
NM_007755  cytoplasmic polyadenylation element binding protein (Cpeb) Prot metab -0.51347 x 0.7 0.0004 
NM_017370  haptoglobin (Hp) Prot metab -0.51060 x 0.702 0.0175 
NM_008862  protein kinase inhibitor, alpha (Pkia) Prot metab -0.50431 x 0.705 0.0400 
NM_016762  matrilin 2 ECM -050199 x 0.706 0.0341 
NM_010390  major histocompability complex Q1b Immun -0.50045 x 0.707 0.0203 
NM_008242  forkhead box D1 (Foxd1) Transcript -0.50023 x 0.707 0.0268 
NM_008785 serine (or cysteine) proteinase inhibitor, Clade A, member 5 (Serpina5)  Prot metab -0.49974 x 0.707 0.0366 
  NM_009154  semaphorin 5A (Sema5a) Migr -0.49740 x 0.708 0.0409 
  NM_020621  pyrimidinergic receptor P2Y, G-protein coupled, 4 (P2ry4) Recept -049545 x 0.709 0.0116 
  M12233  actin, alpha 1, skeletal muscle (Acta1) MCm -0.49534 x 0.709 0.0005 
  NM_008522.1  lactotransferrin (Ltf) Immun -0.49078 x 0,712 0.0160 
  NM_053253.1  Blu protein (Blu) Immun -0.48146 x 0,716 0.0231 
  NM_009144.1  secreted frizzled-related sequence protein 2 (Sfrp2) Prolif, EMT -0.47671 x 0,719 0.0211 
  NM_011347.1  selectin, platelet (Selp) Recept, Adh -0.47634 x 0,719 0.0034 
  NM_019662.1  Ras-related associated with diabetes (Rrad) Enz, GTPase -0.47134 x 0,721 0.0293 
  NM_013669.1  synaptosomal-associated protein, 91 kDa (Snap91) Synapse marker -0.46817 x 0,723 0.0235 
  NM_024406.1  fatty acid binding protein 4, adipocyte (Fabp4) Lipog -0.46752 x 0,723 0.0406 
  AF357883.1  homeodomain transcription factor (Nkx6-1) Transcript -0.46167 x 0,726 0.0169 
  AF020738.1  fibroblast growth factor-related protein FGF-12A (Fgf12) Sign -0.45776 x 0,728 0.0439 
  NM_022881.1  regulator of G-protein signaling 18 (Rgs18) Signaling Regul -0.45263 x 0,731 0.0325 
  NM_021467.2  troponin I, skeletal, slow 1 (Tnni1) MCm -0.44982 x 0,732 0.0163 
  NM_019417.1  PDZ and LIM domain 4 (Pdlim4) Prot metab -0.44649 x 0,734 0.0225 
  NM_010769.1  matrilin 1, cartilage matrix protein 1 (Matn1) ECM -0.44476 x 0,735 0.0280 
  NM_019738.1  nuclear protein 1 (Nupr1) Transcript -0.44316 x 0,736 0.0051 
  NM_023113.1  aspartoacylase (aminoacylase) 2 Enz, Prot metab -0.43938 x 0,737 0.0050 
  NM_010669.1  keratin complex 2, basic, gene 6b (Krt2-6b), Epm -0.43792 x 0,738 0.0065 
  NM_130895.1  adenosine deaminase, RNA-specific, B1 (Adarb1) Enz -0.42746 x 0,744 0.0152 
  NM_031160.1  ADP-ribosylation factor 4-like (Arf4l) Signaling Regul -0.42584 x 0,744 0.0229 
  NM_011582.1  thrombospondin 4 (Thbs4) ECM -0.42420 x 0,745 0.0242 
  AF071068.1  aromatic-L-amino-acid decarboxylase Enz -0.42030 x 0,747 0.0194 
  NM_010016.1  decay accelerating factor 1 (Daf1) Immun -0.41955 x 0,748 0.0062 
  NM_011459.1  serine protease inhibitor 8 (Spi8) Enz -0.41851 x 0,748 0.0025 
  NM_007940.1  epoxide hydrolase 2, cytoplasmic (Ephx2) Enz, Detox -0.41824 x 0,748 0.0242 
  NM_007689.1  chondroadherin (Chad) ECM -0.41822 x 0,749 0.0327 
 772 
 Abbreviations: Funct. Cat., functional category of gene product; Adh, adhesion molecule; Detox, detoxification and 773 
xenobiotic metabolism; ECM, extracellular-matrix component or metabolism; Epm, epithelial marker; Enz, enzyme or 774 
enzyme inhibitor; Glycoconj, glycoconjugate metabolism; Immun, immune system; Inter metab, intermediary metabolism; 775 
Lipog, lipogenesis; MCm, muscle cell marker, Migr, cell migration; Prot metab, protein metabolism; Recept, receptor; Regul, 776 
regulator; Retino metab, retinoid metabolism, Signal, signaling molecule; Transcript, transcription factor or regulator; 777 
Transport, transporter molecule.  778 
Genes with name and symbol in bold character had changes checked by RT-qPCR. 779 
 780 
781 
Table 6. Comparison of RT-qPCR data normalization by 18S rRNA and Hprt1 mRNA. Developmental 782 
changes of expression levels in the lung of 4 genes of interest (2 up-regulated and 2 down-regulated 783 
genes given as examples) are presented (arbitrary unit of 2-ΔΔct related to the expression of a 784 
calibrator sample). 785 
 786 
 Adrenomedullin Bone sialoprotein C1qtnf3 Crabp1 
Reference gene 18S Hprt1 18S Hprt1 18S Hprt1 18S Hprt1 
Day 0 0.51±0.11 0.72±0.13 0.25±0.07 0.40±0.15 0.61±0.18 1.10±0.50 0.02±0.00 0.03±0.01 
Day 4 0.13±0.03* 0.20±0.01* 1.22±0.09* 2.33±0.67* 1.99±0.42* 3.42±0.46* 0.08±0.02* 0.14±0.03* 
Day 7 0.50±0.16* 0.59±0.02* 1.04±0.26 1.33±0.19* 1.10±0.11* 1.55±0.21* 0.46±0.03* 0.67±0.12* 
Day 10 0.75±0.30 1.10±0.26 0.66±0.22* 1.07±0.29 0.85±0.16 1.72±0.46 0.71±0.16* 1.27±0.15* 
Day 14 0.49±0.13 1.52± 0.17 0.04±0.01* 0.13±0.01* 0.35±0.06* 1.34±0.15 0.83±0.10 3.19±0.26* 
Day 20 0.21±0.04* 0.76±0.11* 0.01±0.00* 0.04±0.01* 0.22±0.08 0.77±0.09* 0.33±0.09* 1.27±0.06* 
Day 28 0.17±0.04 0.51±0.17 0.01±0.00 0.02±0.01 0.25±0.09 0.69±0.17 0.09±0.01* 0.29±0.05* 
Adult 0.06±0.02* 0.36±0.05 0.01±0.00 0.02±0.01 0.05±0.02* 0.34±0.06* 0.01±0.00* 0.03±0.02* 
 787 
Mean ± se on 4 individual determinations per stage.*Significant difference from preceding stage (P<0.05 by U test). 788 
Gene symbols: C1qtnf3 = C1q and tumor necrosis factor related protein 3; Crabp1: cellular retinoic acid binding protein 1.789 
Table 7. RT-qPCR determination of expression levels of 11 selected genes found to be up regulated by 790 





transcript level (2∆∆Ct) 
 
% of mean control level per litter 
 control pups   double-transgenic pups control pups double-transgenic pups 
Angiogenesis     
Adrenomedullin 2.16 ± 0.26 
 
14.23 ± 2.59*** 100.0 ± 9.6 686.1 ± 136.1*** 
Wnt2 2.47 ± 0.32 5.54 ± 0.74*** 
 
100.0 ± 7.5 242.5 ± 39.4** 
 
ECM components     
Bone sialoprotein 1.95 ± 0.20 4.99 ± 0.70*** 
 
100.0 ± 7.7 281.4 ± 61.6** 
 
Fibulin 1 1.83 ± 0.23 2.91 ± 0.23* 
 
100.0 ± 6.9 168.6 ± 14.7** 
 
Cell migration     
Snai1 2.54 ± 0.38 
 
3.97 ± 0.42* 
 
100.0 ± 8.1 161.4 ± 16.2** 
 
Snai2 2.42 ± 0.31 5.51 ± 1.21* 
 
100.0 ± 8.1 242.4 ± 59.8* 
 
Ptger2 1.31 ± 0.12 
 
2.31 ± 0.26** 
 
100.0 ± 7.0 176.5 ± 20.7** 
 
Antioxidant mech.      
Gstm5 1.69 ± 0.21 
 
5.09 ± 0.86*** 
 
100.0 ± 7.7 321.43 ± 64.2** 
 




100.0 ± 12.3 263.17 ± 52.7** 
 
Other     
CD36 antigen 2.37 ± 0.42 
 
4.97 ± 0.74** 
 
100.0 ± 10.7 250.8 ± 38.0** 
 
Hsd11b1 1.33 ± 0.14 6.10 ± 1.17*** 
 
100.0 ± 8.5 491.0 ± 102.1*** 
 793 
Mean ± se on 10 control pups and 11 double-transgenic pups from 5 different litters. Difference with control group (one-794 
tailed t test for unpaired data) for: *P<0.05; ** P<0.01; *** P<0.001. Genes are presented in decreasing order of stimulation 795 
gained from microarray analysis. Gene symbols: Hsd11b1 = hydroxysteroid 11-beta dehydrogenase 1; Gstm5 = glutathione 796 
S-transferase, mu5; Wnt2 = wingless-related MMTV integration site 2; Snai = snail homolog; PgEPR EP2 = prostaglandin E 797 





Table 8. RT-qPCR determination of expression levels of 10 selected genes found to be down regulated 803 





transcript level (2∆∆Ct) 
 
% of mean control level per litter 
 control pups double-transgenic pups control pups double-transgenic pups 
Adipocyte and/or alveolar 
typeII-cell markers 
    
C1qtnf3 1.10 ± 0.16 
 
0.62 ± 0.19* 
 
100.0 ± 8.6 50.9 ± 12.7** 
 
Stearoyl-CoA desaturase 1 1.83 ± 0.24 0.57 ± 0.06*** 
 
100.0 ± 9.7 30.7 ± 3.4*** 
 
Abca3 1.52 ± 0.49 
 
0.84 ± 0.32*** 100.0 ± 20.9 54.8 ± 15.6*** 
Other epithelial-cell 
markers 
    
Cyp1b1 1.31 ± 0.18 0.96 ± 0.12* 
 




1.24 ± 0.20 1.29 ± 0.14 ns 100.0 ± 7.9 93.4 ± 13.7 ns 
ECM and ECM metabolism     
Osteoglycin 1.92 ± 0.33 
 
1.70 ± 0.43ns 
 
100.0 ± 10.8 94.2 ± 24.1ns 
 
Fap/seprase 1.60 ± 0.90 
 
1.51 ± 0.99ns 
 
100.0 ± 8.1 104.4 ± 28.0ns 
 
Cell migration/invasion     
Doublecortin 1.80 ± 0.20 
 
1.13 ± 0.28* 
 
100.00 ± 9.89 63.0 ± 16.9* 
 
Retinoic acid metabolism     
Crabp1 1.74 ± 0.17 0.72 ± 0.26** 
 
100.0 ± 7.5 41.4 ± 19.9** 
 
Aldh1a1 1.83 ± 0.18 2.29 ± 0.45 ns 
 
100.0 ± 8.1 133.1 ± 27.9 ns 
 
 806 
Mean ± se on 10 control pups and 11 double-transgenic pups from 5 different litters. Difference with control group (one-807 
tailed t test for unpaired data) for: *P<0.05; ** P<0.01; *** P<0.001; ns = not significant. Genes are presented in decreasing 808 
order of inhibition gained from microarray analysis. Gene symbols and abbreviation: C1qtnf3 = C1q and tumor necrosis 809 
factor related protein 3; CoA = coenzyme A; Abca3 = ATP-binding cassette transporter ABCA3; Fap = fibroblast activation 810 
protein; Crabp1: cellular retinoic acid binding protein 1; Sox2 = SRY-box containing gene 2; Aldh1a1 = aldehyde 811 
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